Expression of functional active Toll like receptor 4 in normal and adenomatous pituitary cells by Tichomirova, Maria
1From: Max Planck Institute of Psychiatry
Director: Professor Dr. Dr. F. Holsboer
Expression of functional active Toll like receptor 4 in
normal and adenomatous pituitary cells
Dissertation
for the attainment of the title Medical Doctor
from the Faculty of Medicine,
 Ludwig-Maximilians-University, Munich
Submitted by
Maria Tichomirova
from Nizhni Novgorod, Russia
2004
2Mit Genehmigung der Medizinischen Fakultät
Der Universität München
Berichterstatter: Prof. Dr. med. G. K. Stalla
Mitberichterstatter: Prof. Dr. H. P. Schwarz
Prof. Dr. W. Machleidt
Mitbetreuung durch den
Promovierten Mitarbeiter: Dr. U. Renner
Dekan: Prof. Dr. med. Dr. h. c. K. Peter
Tag der mündlichen Prüfung: 18.03.2004
3To my Mother and in memory of my Father
4ACKNOLEGMENTS
I would like to thank:
Prof. Dr. Dr. Holsboer for giving me the opportunity to work in this Institute.
The Head of our group, Prof. Dr. Günter K. Stalla, for giving me the possibility to
make this work in his lab. Without his advice and inspiration this thesis would not
have been written.
My main supervisor, Dr. Ulrich Renner, who has proposed this research project and
has provided me with his advice and who was always next to me during the
completion of the thesis.
Prof. Dr. med. P. Bottermann for introducing me to the field and supporting during the
first years of my studies.
Dr. Marcelo Paez-Pereda and Dr. Marily Theodoropoulou for numerous stimulating
discussions, help with experimental setup and general advice, and for being friends.
Manuela Feier and Johanna Stalla for helping me with their excellent technical
expertise.
Michel Spruyt for constant encouragement and love.
Lastly, and most importantly, I wish to thank my mother, Ludmila Tichomirowa-
Epstein for all her love and support.
5CONTENTS
1. INTRODUCTION................................................................................................................................. 8
1.1.THE PITUITARY GLAND ...................................................................................................................... 8
1.2 PITUITARY ADENOMAS ...................................................................................................................... 9
1.2.1. Classification .......................................................................................................................... 9
1.2.1.1. Functional classification.................................................................................................................. 9
1.2.1.2. Radiological/ surgical classification............................................................................................... 12
1.2.1.3. Histological classification .............................................................................................................. 12
1.2.2. Pituitary tumourigenesis ....................................................................................................... 12
1.2.2.1. Growth factors .............................................................................................................................. 15
1.3. INTERLEUKIN-6 EXPRESSION AND ACTION IN PITUITARY. .................................................................. 16
1.4. TOLL-LIKE RECEPTORS .................................................................................................................. 18
1.5. AIM OF THE STUDY ........................................................................................................................ 20
2. MATERIAL AND METHODS ............................................................................................................ 21
2.1. REAGENTS.................................................................................................................................... 21
2.2. SOLUTIONS................................................................................................................................... 24
2.3 PATIENTS....................................................................................................................................... 26
2.4 TISSUE PREPARATION AND CELL CULTURE ....................................................................................... 27
2.5. CELL PROLIFERATION AND VIABILITY ............................................................................................... 28
2.6. GENE EXPRESSION STUDIES .......................................................................................................... 29
2.6.1. RNA extraction ..................................................................................................................... 29
2.6.2. Reverse transcriptase – polymerase chain reaction (RT-PCR)........................................... 30
2.6.3. In situ hybridization .............................................................................................................. 32
2.6.3.1. Principle. ....................................................................................................................................... 32
2.6.3.2. Protocol for cryostat sections........................................................................................................ 34
2.7. PROTEIN STUDIES ......................................................................................................................... 36
2.7.1. Immunohistochemistry ......................................................................................................... 36
2.7.1.1. Principle........................................................................................................................................ 36
2.7.1.2. Primary antibodies ........................................................................................................................ 36
2.7.1.3. Protocol for cryostat sections........................................................................................................ 37
2.8 TRANSFECTION STUDIES................................................................................................................. 39
2.8.1. Plasmid preparation ............................................................................................................. 39
2.8.2. Cell transfection.................................................................................................................... 39
2.8.3. Reporter assay ..................................................................................................................... 40
2.9. STIMULATION AND MEASUREMENT OF IL-6 IN PITUITARY ADENOMA CELL CULTURES .......................... 40
2.10. HORMONE SECRETION STUDIES ................................................................................................... 40
2.11. STATISTICS................................................................................................................................. 41
63. RESULTS.......................................................................................................................................... 42
3.1. EXPRESSION OF TLR4 IN PITUITARY CELL LINES .............................................................................. 42
3.2. EXPRESSION OF TLR4 IN NORMAL AND TUMORAL HUMAN PITUITARY................................................. 43
3.3. EFFECT OF LPS ON PROLIFERATION IN ATT20 AND GH3 CELLS...................................................... 48
3.4. EFFECT OF LPS ON HORMONE PRODUCTION IN ATT20 AND GH3 CELLS.......................................... 53
3.5. EFFECT OF LPS ON IL-6 SECRETION BY PITUITARY ADENOMA CELL CULTURES ................................. 54
3.6. EFFECT OF PACLITAXEL (TAXOL) ON THE CELL PROLIFERATION AND HORMONE SECRETION IN ATT20
CELLS. ................................................................................................................................................. 57
4. DISCUSSION .................................................................................................................................... 58
5. SUMMARY ........................................................................................................................................ 69
6. REFERENCE LIST............................................................................................................................ 73
7ABBREVATIONS
Abbreviation Definition
ACTH Adrenocortocotrophic hormone
BMP-4 Bone morphogenetic protein
bp Base pair
cAMP Cyclic adenosine mono-phosphate
ECM Extracellular matrix
EGF Epidermal growth factor
FGF Fibroblast growth factor
FS Folliculostellate cells
FSH Follicle stimulating hormone
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GH Growth hormone
IHC Immunohistochemistry
IGF-I insulin-like growth factor
ir Immunoreactivity
IL-6 Interleukin 6
ISH In situ hybridization
LH Luteinizing hormone
LIF Leukemia inhibitory factor
LPS Lipopolysaccaride
MAPk Mitogen activated protein kinase
NFκB Nuclear factor kappa-B
NGF Nerve growth factor
POMC Proopiomelanocortin
PCR Polymerase chain reaction
PRL Prolactin
RNA Ribonucleic acid
RT Reverse transcriptase
RT-PCR Reverse transcription PCR
TGF Tumour growth factor
Tlr4 Toll like receptor 4
TSH Thyroid stimulating hormone
81. INTRODUCTION
1.1 The pituitary gland
The pituitary gland controls various homeostatic functions, such as metabolism,
growth and reproduction, through consolidating the signals from the brain to different
endocrine organs. The pituitary is located under the brain in the sella turcica and
consists of the adenohypophysis and the neurohypophysis. Subdivided into the
anterior and intermediate lobes the adenohypophysis consists of six
adenohypophysal cell types, which secrete hormones, namely corticotrophs,
somatothrophs, lactotrophs, mammosomatotrophs, thyrotrophs and gonadotrophs.
Also present in the pituitary are folliculostellate cells (FS), an astrocyte-like cell type
of unknown origin and poorly understood function. Corticotrophs secret adrenal
corticotropic hormone (ACTH), that stimulates the secretion of glucocorticoids in the
adrenal. Somatothrophs produce growth hormone (GH), which stimulates bone and
muscle growth directly through GH receptors or indirectly through the stimulation of
an insulin-like growth factor (IGF-1). Lactotrophs release prolactin (PRL), which
stimulates lactation and inhibits gonadal functions. Mammosomatotrophs synthesise
both GH and PRL and differentiate into somatothrophs during growth phases and
into lactotrophs during pregnancy (Asa and Ezzat, 2002). Thyrotrophs secret thyroid
stimulating hormone (TSH), which stimulates the production of thyroid hormones by
the thyroid gland. Gonadotrophs synthesise follicle-stimulating hormone (FSH) and
luteinizing hormone (LH), which are in charge of germ-cell development and sex
steroids production in the gonads. FS cells do not produce any hormones, but a
number of different growth factors and cytokines, which act by paracrine mechanisms
on hypophyseal endocrine cells.
91.2 Pituitary adenomas
Human pituitary adenomas develop typically from cells of the adenohypophysis and
are usually non-metastasising tumours with a significant minority of cases, exhibiting
a more aggressive behaviour (Pardo et al., 2001). Pituitary tumours comprise 10-
15% of intracranial tumours at surgery and 6 to 23 % of intracranial tumours at
autopsy (Kovacs and Horvath, 1987). Patients with pituitary neoplasm could have
symptoms of a mass lesion (headache, visual field disturbances, ophthalmoplegia,
facial pain from compression of the first or second branch of the trigeminal nerve,
anterior pituitary insufficiency) or endocrine abnormality (hyper-or hypofunction, or
combination of the two), or both.
1.2.1. Classification
The classification of pituitary adenomas can be functional, anatomic/ radiological,
histological, immunohistochemical, ultrastuructural, clinicopathologic.
1.2.1.1. Functional classification
Depending on hormone excess and clinical symptoms, pituitary tumours can be
hormonally inactive (HI) or hormonally active. The latter can be subdivided into
prolactinomas, somatotrophinomas, corticotrophinomas, gonadotrophinomas and
thyreotrophinomas (table 1).
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Table 1. Epidemiology of clinical manifest pituitary adenomas (adapted from
Jockenhövel 2002)
Adenoma Prevalence
per100 000
Incidence per
100 000/year
Percentage of
adenomas
Prolactinoma 30-50 2-5 55%
Hormone inactive 6-10 1 30%
Somatotrophinoma 5-7 <1 10%
Corticotrophinoma 1-3 <1 5%
Thyreotrophinoma 1 <1 1%
Gonadotrophinoma 1 <1 1%
All adenomas 40-70 6-8 100%
Somatotrophinomas cause gigantism before the end of puberty and acromegaly in
adults by hypersecretion of GH, resulting in an elevated level of circulating IGF-1.
Acromegaly is an insidious, chronic disease, characterised by bony and soft tissue
overgrowth. Common clinical symptoms include headache, excessive perspiration,
fatigue, paresthesiae, weakness, joint pain, and weight gain. Patients may also
present with osteoarthritis, carpal tunnel syndrome, visual abnormalities, sleep
apnoea, or reproductive disorders (Nabarro, 1987). Transsphenoidal surgical
resection is the therapy of the first choice. The treatment with somatostatin
analogues can supress GH secretion and cause tumour volume reduction, but to
reveal the role of somatostatin analogues as primary therapy of acromegaly need
further studies.
Prolactinomas are associated with hyperprolactinaemia. Most patients experience a
high prolactin level, which usually parallel the size of tumour, hypogonadism with
subsequent infertility, galactorrhoea, sexual dysfunction and osteoporosis. Most
prolactinomas show good response to dopamine agonists, although there are few
cases with resistance to dopamine-like drugs. Reduction of dopamine - binding sites
or even an absence of dopamine D2 receptors has been demonstrated in
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prolactinomas from patients, which were resistant to dopamine treatment (Caccavelli
et al., 1994).
Corticotrophinomas cause Morbus Cushing or Nelson syndrome, usually present with
endocrinological manifestation rather than a mass effect, since they are mostly
microadenomas. ACTH overproduction leads to glucorticoid excess from adrenal,
resulting in symptoms of Cushing’s syndrome, such as weight gain, truncal obesity,
plethoric “moon face”, the “buffalo hump”, thinning extremities with muscle atrophy,
thin skin, hypertension and psychological disturbances. Nelson syndrome is a
syndrome characterised by increased skin pigmentation, visual defects secondary to
compression of the optic chiasm, and elevated serum levels of ACTH following
adrenalectomy for Cushing’s syndrome. The cause of this syndrome is the expansion
of an underlying ACTH-secreting pituitary adenoma. Transsphenoidal surgery is the
treatment of choice in corticotrophinomas.
TSH- secreting pituitary tumours are associated with signs and symptoms of either
hyperthyroidism or mass effects. Transsphenoidal surgery is the treatment of first
choice although octreotide treatment can normalise TSH levels and induce tumour
shrinkage (Beck-Peccoz et al., 1996).
Hormone inactive pituitary adenomas produce no hormones and, therefore, have no
typical hormone excess-related presentation. At diagnosis, patients already have
very large tumours, presenting ocular or neurological symptoms rather than
endocrinological disturbances. Transsphenoidal surgery is the best way to treat these
tumours. In the case of incomplete resection radiation therapy should follow. It has
further been shown, that the risk of adenoma recurrence could be reduced with
postoperative radiotherapy (Snyder, 1995). However, the treatment with either
dopamine or somatostatin agonists may be advantageous to prevent tumour
regrowth in patients who have already received conventional therapies.
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1.2.1.2. Radiological/ surgical classification
According to Hardy’s classification adenomas are classified in five grades and in 6
stages (Hardy, 1979): Grade I refers to microadenomas, i.e. <10mm in diameter;
Grade II refers to macroadenomas (>10 mm in diameter); Grade III adenomas with
local perforation of sellar floor ; Grade IV diffuse perforation of cellar floor, distant
spread. Grade V spread by CSF/blood. Tumour stage 0: None, A: suprasellar
extension, B: third ventricle recess obliterated, C: parasellar, III ventricle grossly
displaced, D: intracranial/intradural, E: cavernous sinus/extradural.
1.2.1.3. Histological classification
By cytoplasmatic staining, immunohistochemical staining for hormones and by
electron microscopy, hormone active  and inactive adenomas can be subdivided in
different subtypes (table 2).
1.2.2. Pituitary tumourigenesis
In spite of intensive study during the last decades the pathogenetic mechanism of
pituitary adenomas still remains unclear.
Pituitary adenomas are monoclonal in origin, which means that tumours originate
from a single transformed cell (Herman et al., 1990), but the cause of the tumour
transformation is still unknown.
Two hypotheses have been discussed with respect to pituitary adenoma formation.
Pituitary cells are regulated by hypothalamic factors, peripheral hormones and
growth factors; thus dysregulation of these signalling pathways could be a cause of
tumour development. On the other hand the intrinsic pituitary events, such as an
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activating mutations protoncogene or an inhibiting mutations in the tumour
suppresser gene, could promote of a clonal expansion and result in adenoma
formation (Fig.1).
Table 2. Histological classifications of pituitary adenomas.
 Adenoma Type Staining Immunohistology Blood
hormone
levels
Clinical symptoms
Corticotrophinomas
densily granulated
sparsely granulated
B
C
ACTH, MSH
Endorphins
ACTH Morbus Cushing or
Nelson syndrome
Silent corticotrophinomas
subtype I
subtype II
B/C
C
ACTH, MSH
Endorphins
None Mass symptoms
Somatotrophinomas
densily granulated
sparsely granulated
A
C/A
GH
α-subunit
GH Acromegaly or
gigantism
GH and PRL-producing
mixed GH-PRL
mammosomaotrophinoma
acidophilic stem cells
A/C
A
C
GH, PRL
α-subunit
GH,PRL
Acromegaly or
gigantism ±
hyperprolactinaemia
Acromegaly ±
hyperprolactinaemia
hyperprolactinaemia
or occasional
acromegaly
Prolactinomas
densily granulated
sparsely granulated
A
C
PRL PRL Hyperprolactinaemia
Thyreotrophinomas C/B TSH
α-subunit
± TSH Hyperthyroidism
Gonadotrophinomas C/B FSH, LH
α-subunit
None Mass symptoms
Null cell adenomas
non-oncocytic
oncocytic
C
A
None None Mass symptoms
Abbreviations: A, acidophilic; B, basophilic, C, chromophobic
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Gene Human defect Human phenotype
Gain of function
Gsα
RAS
PKC
PRKAR1
Pdt-FGFR4
PTTG1
Germline and somatic activating
mutations
Somatic activating mutations
Somatic activating mutations
Truncation mutations
Alternative transcription initiation
Unknown
Somatotroph adenomas
Pituitary carcinomas
Somatotroph adenomas
Carney´s complex
somatotroph
hyperplasia/adenoma
All adenomas
All adenomas
Loss of function
MEN1
RB
CDKN2A
CDKN1B
ZAC
Inactivating mutations
Promoter methylation
Promoter methylation
Diminshed expression
? Mechanism
Diminshed expression
Adenomas
Adenomas
Adenomas
Corticotroph and
reccurrent adenomas
HIMutation
Mutation
Hormones stimulation
or inhibition
H
or
m
on
es
 s
tim
ul
at
io
n
or
 in
hi
bi
tio
n
Growth factors
Hormones
Growth factors
Growth factors
Carcinoma
RAS
activation
Fig. 1.  Proposed model of pituitary tumourigenesis, showing the concept of the
hormonal stimulation theory (left pathway) vs. the intrinsic pituitary defect theory
(right pathway). In animal models and patients, hypophysiotrophic hormone excess
or growth factor overexpression induce hyperplasia, which may predispose the cells
to mutation and may lead to adenoma formation. However, most human pituitary
adenomas are unassociated with hyperplasia and may therefore originate from
genetic events in a cell that becomes more responsive to hormones and growth
factors, resulting in clonal expansion. In the box are shown pituitary gain- and loss- of
function events that could be responsible for transforming mutation.
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1.2.2.1. Growth factors
Pituitary cells have been shown to produce various growth factors and cytokines and
express their corresponding receptors (Tab. 3). These factors may regulate pituitary
cell proliferation and hormone secretion in an autocrine/ paracrine fashion (Renner et
al., 1996; Ray and Melmed, 1997)
Table 3. Overview of the expression of the most relevant growth factors and
cytokines in normal pituitary and pituitary tumours .
Growth factors and
cytokines
Expression in
normal pituitary
Expression in pituitary adenomas
TGF-β1 L, FS reduced expression in rat prolactinomasa
TGF-β3 L, FS increased expression in rat prolactinomasa
Activin G expressed in human inactive and
gonadotroph adenomas
Inhibin G expressed in human inactive and
gonadotroph adenomas
Follistatin FS reduced expression in human gonadotroph
adenomas
BMP-4 n.k. over-expression in mice prolactinomasb
and human prolactinomas
EGF G,S, C, T no over-expression in human pituitary
adenomas
TGF-α G,S, C, T over-expression in rat prolactinomasa
FGF-2 FS,L over-expression in rat prolactinomasa
NGF L reduced expression in dopamine resistant
human prolactinomas
IL-6 FS tumour cell-derived production in the
majority of human pituitary adenomas
LIF C,FS reduced expression in human
prolactinomas
a) Estradiol-induced prolactinomas in Fischer 344 rats. b) Prolactinomas in dopamine D2
receptor knock-out mice. Abbreviations: C, corticotroph cells; FS, folliculostellate cells; G,
gonadotroph cells; L, lactotroph cells; S, somatotroph cells; T, thyreotroph cells, n.k. , not
known. For abbreviations of growth factors see front page.
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This has led to the hypothesis that in pituitary adenomas, excessive hormone
production and the loss of growth control is a consequence of altered expression of
cytokines/growth factors and /or their receptors resulting in disturbances of auto-
paracrine regulation. Interleukin-6 is supposed to be one of these factors.
1.3. Interleukin-6 expression and action in pituitary.
 IL-6 is produced in the normal pituitary by folliculostellate cells (Renner et al., 1998),
whereas in the majority of pituitary adenomas, in which FS cells are rare or absent,
tumour cells are the source of IL-6 (Jones et al., 1994). It is a potent stimulator of
secretion for nearly all the hormones in the normal pituitary and contributes to
excessive ACTH production in corticotroph adenomas (Arzt et al., 1999; Renner et
al., 1996; Pereda et al., 2000). Interestingly, IL-6 inhibits the growth of normal
pituitary cells (Arzt et al., 1993) but differently regulates c-fos expression in pituitary
adenomas (Pereda et al., 1996) and stimulates pituitary tumour cell proliferation (Arzt
et al., 1993). IL-6 is linked through gp130 to different signalling pathways such as the
JAK/STAT pathway or the MAP kinase (MAPk) pathway, however, gp130 also
induces cytokine-signalling inhibitors like SOCS-3 (Arzt, 2001). Although the
underlying mechanism for the opposing growth effects of IL-6 in normal and
adenomatous pituitary cells has not yet been studied, differences in the induction of
activating signal pathways or stimulation of cytokine-signalling inhibitor production by
the IL-6/gp130 complex may be responsible for the different mitogenic effects of IL-6
in the normal and adenomatous pituitary. The intratumoral production of tumour cell
growth-stimulating IL-6 in the majority of pituitary adenomas, makes this cytokine an
attractive candidate as an auto-/paracrine stimulator of adenoma progression.
Bacterial endotoxin (LPS), IL-1, tumour necrosis factor α (TNF- α), pituitary adenylate
cyclase-activating peptide (PACAP), vasoactive intestinal peptide (VIP) and
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calcitonin all stimulate IL-6 production in pituitary (Arzt et al., 1999; Lohrer et al.,
2000; Kiriyama et al., 2001). In addition, glucorticoid receptors expressed in FS cells
(Ozawa et al., 1999) induce the potent inhibition of glucorticoids on IL-6 production
(Lohrer et al., 2000; Vankelecom et al., 1989).
Understanding of the mechanism of IL-6 action to alter pituitary function was made
possible by using lipopolysaccharide (LPS), a component of the outer layer of the cell
wall of gram-negative bacteria (Raetz, 1990), a potent activator of the immune
system (Rietschel and Brade, 1992). LPS induces the production of tumour necrosis
factor (TNF)-α, IL-1 and IL-6 from macrophages and monocytes (van Deventer et al.,
1990) and coupling to LPS binding protein (LBP) enhances its stimulatory potency
(Hailman et al., 1994). Free LPS or LPS/LBP complex bind to the membrane-bound
CD 14 (mCD14) in macrophages and monocytes (Ulevitch and Tobias, 1995). The
LPS/LBP/CD14 complex in turn interact with the toll-like receptor-4 (Tlr4), a member
of the toll receptor family (Medzhitov et al., 1997; Poltorak et al., 1998).
We have recently shown that pituitary folliculostellate (FS) cells expressed both
CD14 and Tlr4. LPS could stimulate IL-6 production in these cells through the p38
MAPk/NF-kB pathway (Lohrer et al., 2000). Moreover, LPS-stimulated, FS cell-
derived IL-6 was shown to enhance the ACTH production in three-dimensional
pituitary re-aggregate cell culture in paracrine manner (Gloddek et al., 2001).
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1.4. Toll-like receptors
Members of the Toll-like receptor (TLR) family expressed on immune cells are
critically involved in the innate immune response interacting differently and in part
specifically with cell wall components or DNA of gram-negative and gram-positive
bacteria or with viral components. More than 10 members of the TLR family can be
found in a search of human and mouse public data basis and ten members have
been reported (Akira et al., 2001). Tlr4 and Tlr2 activate immune cells in response to
components of the cell gram-negative (predominantly LPS) and gram-positive
(predominantly lipoproteins) bacteria, respectively. Tlr9 is activated by unmethylated
CpG motifs of bacterial DNA.
TLR have not only been found on immune cells, but in other cells as well ,e.g. Tlr4
expression relatively high in the heart (Frantz et al., 1999). It was found that the
expression of Tlr4 and Tlr2 increased in fetal mouse lung with age (Harju et al.,
2001). TLR expression was also observed in vascular endothelial cells (Hijiya et al.,
2002), adipocytes (Lin et al., 2000), intestinal (Abreu et al., 2002) and renal (Tsuboi
et al., 2002) epithelial cells, microglia cells (Bsibsi et al., 2002).
Taxol (Paclitaxel) is a potent anti-cancer drug and the most effective compound in
the treatment of mammacarcinomas, tumours of female reproductive organs and a
number of other human neoplasias. In mice it has been shown that taxol mimics the
effect of LPS and acts anti-proliferative and pro-apoptotic through Tlr4 (Byrd-Leifer et
al., 2001); whether this is also the case in humans is still controversially discussed.
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Fig.2. Toll receptor signalling pathway. Human Tolls contains extracellular leucine-
rich repeat domains of the IL-1 receptor (IL-1R), which are designated as Toll/IL-1R
(TIR) domains. Mammalian Toll-like receptors signal through the adapter protein
MyD88, which, in turn, associates with the serine threonine proteine kinase IL-1R-
associated kinase (IRAK). Recruitment of IRAK leads to it activation and association
with another adapter protein, tumour necrosis factor receptor-associated factor
(TRAF 6), that activates downstream kinases. Oligomerization of TRAF6 results in
activation of IkB kinases, followed by phosphorilation and degradation of IkB. On IkB
degradation, NFkB factors translocate into the nucleus, where they induce
transcription of target genes. In addition, to NFkB activation, TLRs can also initiate
mitogen-activated protein kinase signalling cascades, which activate multiple
transcription factors, including activator protein1 (cJUN) and ELK1 (Akira, 2003).
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1.5. Aim of the study
The study described herein aims to investigate the expression of receptors for LPS
(Tlr4) in endocrine pituitary cells, pituitary tumour cell lines and human pituitary
adenoma cells, and to study the functionality of Tlr4 in pituitary adenoma cell cultures
and to clarify, whether LPS could act as a pituitary tumour progression factor either
directly or by stimulating intratumoral IL-6 production.
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2. MATERIAL AND METHODS
2.1. Reagents
Product Company
[α-33P]dATP NEN (Cologne, Germany)
ABC blocking kit Vector Laboratories (Burlingane, CA, USA)
Acetic acid MERCK (Darmstadt, Germany)
Acridine orange Sigma (St. Louis. MO, USA)
AG 1478 Calbiochem (Darmstadt, Germany)
Agar Life Technologies (Paisley, UK)
Ammonium persulfate Sigma (St. Louis. MO, USA)
Amphotericin B Biochrom (Berlin, Germany)
Ampuwa water (for ISH) Frisenius (Germany)
5-Aza-2´-deoxycytidine Sigma (St. Louis. MO, USA)
Beta-mercaptoethanol MERCK (Darmstadt, Germany)
Boric acid Roth (Karlsruhe, Germany)
Bovine serum albumin (for cell culture) Invitrogen Corp (Paisley, UK)
Chloroform Sigma (St. Louis. MO, USA)
Collagenase Worthington Biochemical Corp. (Lakewood,
NJ, USA)
DATP Roche (Mannheim, Germany)
DCTP Roche (Mannheim, Germany)
DGTP Roche (Mannheim, Germany)
Diaminobenzidine Sigma (St. Louis. MO, USA)
Diethyl-dicarbonate Sigma (St. Louis. MO, USA)
Dimethyl sulfoxide Sigma (St. Louis. MO, USA)
Dithiothreitol Sigma (St. Louis. MO, USA)
DNAse Invitrogen Corp (Paisley, UK)
dNTP Mix MBI Fermentas (Vilnius, Lithouania)
DTTP Roche (Mannheim, Germany)
Dulbecco’s modified Eagle medium
(DMEM)
Invitrogen Corp (Paisley, UK)
Dulbecco’s modified Eagle medium
(DMEM) without Phenol Red
Sigma (St. Louis. MO, USA)
EDTA MERCK (Darmstadt, Germany)
Entellan MERCK (Darmstadt, Germany)
Epidermal growth factor Sigma (St. Louis. MO, USA)
Ethidium bromide Sigma (St. Louis. MO, USA)
Fetal calf serum Gibco (Karlsruhe, Germany)
Formamide Sigma (St. Louis. MO, USA)
Forskolin Sigma (St. Louis. MO, USA)
Glucose MERCK (Darmstadt, Germany)
Guanidine thiocyanate Fluka Chemie AG (Buchs, Switzerland)
Hepes Sigma (St. Louis. MO, USA)
Hexanucleotide Mix Roche (Mannheim, Germany)
Hexanucleotide Mix Roche (Mannheim, Germany)
Hyaluronidase Sigma (St. Louis. MO, USA)
Hydrochloric acid MERCK (Darmstadt, Germany)
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Hydrogen peroxide Roth (Karlsruhe, Germany)
Isoamylalcohol MERCK (Darmstadt, Germany)
Isopropanol Sigma (St. Louis. MO, USA)
Isopropanol Sigma (St. Louis, Mo, USA)
KH2PO4 MERCK (Darmstadt, Germany)
Levamisole Sigma (St. Louis. MO, USA)
L-Glutamine Biochrom AG (Berlin, Germany)
Lipofectamine Invitrogen Corp (Paisley, UK)
Luciferin Roche (Mannheim, Germany)
Magnesium chloride MERCK (Darmstadt, Germany)
Marker 1kbPlus Life Technologies (Paisley, UK)
OPTIMEM 1 Invitrogen Corp (Paisley, UK)
Paclitaxel Sigma (St. Lois, Mo, USA)
Paraformaldehyde MERCK (Darmstadt, Germany)
PD 98059 Calbiochem (Darmstadt, Germany)
Penicillin+Streptavidine mix Biochrom AG (Berlin, Germany)
Peptone ICN Pharmaceuticals (Aurora, OH, USA)
Phenol Roth (Karlsruhe, Germany)
Phosphate based buffer
PBS (for cell culture)
Life Technologies (Paisley, UK)
Photoemulsion Ilford K5 (Eppelheim, Germany)
Plasmid Preparation Kit QIAGEN (Hilden, Germany)
Polyacrylamide Invitrogen Corp (Paisle, UK)
poly-L-lysine-coated microscope
slides
(SuperFrost® Plus)
Menzel-Gläser (Braunschweig, Germany)
Potassium chloride (KCl) MERCK (Darmstadt, Germany)
Reisin Bio-Rad (Hercules, CA, USA)
Reporter lysis buffer Promega GmbH (Mannheim, Germany)
Retinoic acid Sigma (St. Louis, Mo, USA)
Reverse transcriptase
(SuperScript II TM )
Invitrogen (Carlsbad, CA, USA)
Sarcosine, N-Lawryl- Sigma (St. Louis, Mo, USA)
SB 203580 Calbiochem (San Diego, CA, USA)
Sodium acetate dihydrate MERCK (Darmstadt, Germany)
Sodium acetate trihydrate MERCK (Darmstadt, Germany)
Sodium chloride (NaCl) Roth (Karlsruhe, Germany)
Sodium dihydrogen phosphate mono-
hydrate
(NaH2PO4-H2O)
MERCK (Darmstadt, Germany)
Sodium hydrogen phosphate
dihydrate (Na2HPO4.2H2O)
MERCK (Darmstadt, Germany)
Sodium peroxide (NaOH) MERCK (Darmstadt, Germany)
Streptavidin R&D systems (Minneapolis, MN, USA)
Taq DNA polymerase MBI Fermentas
TEMED Sigma (St. Louis, Mo, USA)
Terminal transferase Roche (Mannheim, Germany)
Tissue-Tek® Sakura Finetek Europe (Zoeterwoude, The
Nederlands)
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Toluidin Blue Sigma (St. Louis, Mo, USA)
Triethanolamine Sigma (St. Louis, Mo, USA)
Tris pure ICN Pharmaceuticals (Aurora, OH, USA)
Trypsin Sigma (St. Louis, Mo, USA)
Vector Red Vector Laboratories (Burlingane, CA, USA)
WST-1 assay Roche (Mannheim, Germany)
X-ray film Kodak (New Haven, CT, USA)
Xylol Roth (Karlsruhe, Germany)
Yeast extract powder ICN Pharmaceuticals (Aurora, OH, USA)
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2.2. Solutions
Collagenase Mix 1000 U/ml
Collagenase     : 400 mg/ 100ml solution
Trypsin inhibitor: 10 mg/ 100ml solution
Hyaluronidase  : 100 mg/ 100ml solution
BSA                  : 400 mg/ 100ml solution
Dnase               : 500 µl/ 100ml solution
Citric acid monohydrate
(for antigen retrieval)
10mM
Citric acid monohydrate: 2.1 g/L
Adjust to pH 6.0
Formamide deionized Add  Reisin: 5ml/ 50ml Formamide
Formamide/4xSSC buffer Formamide deionized: 50ml/ 100ml solution
SSC 20x sterile          : 20ml/ 100ml solution
DEPC water               : 30ml/ 100 ml solution
HDB buffer Glucose                      : 18 mg/ 100ml solution
Penicillin/Streptavidin : 1 ml/ 100ml solution
Amphotericin B           : 1 ml/ 100ml solution
LB medium Peptone        :10 g/L
Yeast extract: 5 g/L
NaCl             : 5 g/L
NaOH 1M     : 2 ml/L
Adjust to pH 7.0
Luciferase-assay buffer Tris-HCl 1M pH 7.8 : 7.5 ml/ 100ml solution
MgCl2 1M               : 2.5 ml/ 100ml solution
Before use add 4 µl/ml ATP 0.1 M
Paraformaldehyde
(PFA)
4%
paraformaldehyde             :4 g/100 ml
Sodium phosphate buffer : 20 ml/100ml solution
Ampuwa water                  : 80 ml
Add 1M NaOH to pH 7.4
Heat at 56°C to dissolve
Filter and cool before usage
Store at +4°C for maximum 2 days
Phosphate based buffer
(PBS)
1x
NaCl                  : 8 g/L
KCl                    : 0.2 g/L
Na2HPO4.2H2O : 1.44 g/L
KH2PO4             : 0.2 g/L
Adjust to pH 7.4
Sodium acetate 2M
Sodium acetate trihydrate: 27.2 g/ 100ml
DEPC                              : 20 µl
Add acetic acid to pH 4.0
Leave at room temperature overnight
Sodium phosphate buffer 50mM
Na2HPO4.2H2O : 7.06 g/L
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NaH2PO4. H2O  : 1.32 g/L
Adjust to pH 7.4
Solution D 4M Guanidium thiocyanate
25 mM Sodium citrate pH 7.0
0.5% Sarcosyl
dissolved in DEPC
To complete the medium add:
180µl beta-mercaptoethanol/25ml solution
SSC 20x
NaCl : 175 g/L
Sodium citrate dihydrate: 88.23 g/L
Adjust to pH 7.0
Filter and autoclave before use
Tris borate EDTA buffer
(TBE)
10x
Boric acid (H3BO3) : 61.83 g/L
EDTA                     : 37.2 g/L
Tris pure                 : 30.03 g/L
Adjust to pH 8.0
Tris buffer Tris pure: 12.114 g/L
Adjust to pH 7.6
Tris-based buffer
(TBS)
1x
Tris pure : 2.42 g/L
NaCl        : 8 g/L
Adjust to pH 7.6
Tris-HCl 1M
Tris pure: 121.14 g/L
Add 25% HCl to a pH 8.2
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2.3 Patients
The present work was approved by the ethics committee of the Max-Planck-Institute
of Psychiatry (Munich, Germany).
Tumour tissue was obtained by transsphenoidal surgery from 67 patients (23 female,
44 male; aged 14 to 80 years) with hormone-producing (n=42) or hormone-inactive
(n=25) pituitary adenomas. Elevated serum levels of ACTH/cortisol, GH/IGF-I, PRL
and TSH as well as corresponding clinical symptoms were observed in patients with
endocrine-active tumours (10 corticotroph, 18 somatotroph, 12 lactotroph, 2
thyreotroph adenomas). Diagnosis of hormone-active adenomas was further
confirmed by functional endocrine testing. Nuclear magnetic resonance imaging or
computerised tomography showed that all corticotroph tumours were
microadenomas, whereas the remaining hormone-active and all nonfunctioning
tumours were macroadenomas. By routine immunohistochemistry, corresponding
hormone expression was observed in endocrine-active tumour tissue.
Immunohistochemical investigations showed that the group of clinically hormone-
inactive tumours consisted of 4 gonadotropin-immunopositive tumours and 21 null
cell adenomas or oncocytomas. Most of the patients with somatotroph adenomas
had been pre-treated with somatostatin analogues. All of the patients with
prolactinomas had to be operated on due to a resistance to dopamine agonist
therapy.
Normal human pituitary (n=3; 2 female, 1 male; aged 30 to 49), kindly provided by
Prof. W. Eisenmenger from the Institute of Forensic Medicine of the University of
Munich, were obtained during an autopsy. The post mortem delay was less than 16
hours.
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Human tonsils obtained from the Department of Otolaryngology/Head & Neck
Surgery of the Technical University of Munich were used as positive controls in Tlr4
mRNA and protein expression studies.
2.4 Tissue preparation and cell culture
Where possible, human pituitary tumour tissue was devided into three pieces: one
part was used for RNA extraction, another fragment was shock-frozen for in-situ
hybridization (ISH) or immunohistochemistry (IHC), and the third piece was
enzymatically dispersed to establish primary adenoma cell cultures. Normal human
pituitaries were only divided for RNA extraction and ISH/IHC.
For primary pituitary Tudor cell culture, adenoma tissue, obtained at transsphenoidal
microsurgery, were washed several times with HDB buffer. Sliced tissue fragments
were dispersed mechanically and enzymatically in collagenase-mix (Renner et al.,
1994). The cells were washed by repetitive centrifugation and resuspension, and
were finally resuspended in DMEM culture medium (pH 7.3) supplemented with 10 %
heat-inactivated fetal calf serum (FCS), 2.2 g/l NaHCO3, 10 mM HEPES, 2 mM
glutamine, 10 ml/l non essential amino acids, 10 ml/l MEM vitamins, 5 mg/l insulin, 5
mg/l transferrin, 2.5 mg/l amphotericin-B, 105 U/l penicillin/streptomycin, 20 µg/l
sodium selenit, and 30 pM T3 (Henning, Germany). Cell viability was consistently
over 90 % as assessed by acridine orange/ethidium bromide staining. Cells were
plated in 48 well plates (100,000 cells/well in 0.5 ml culture medium) and incubated
for 2 to 3 days in a 5% CO2 atmosphere at 37°C. After the cells had attached to the
plates, stimulation experiments were performed as described below. In most cases,
the small amount of tissue available limited the number of experiments that could be
undertaken with each tumour.
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Rodent and human cell lines were grown routinely in the same medium and under
the same conditions as described above. Tlr4 expression was studied in corticotroph
mouse AtT20 cells, gonadotroph-like mouse αT3-1 cells, lactosomatotroph rat GH3
cells, FS-like mouse TtT/GF cells, FS-like human PDFS cells and hormoninactive-like
HP75 cells. Studies on hormone production and growth were conducted in AtT20 and
GH3 cells.
2.5. Cell proliferation and viability
Cell proliferation was measured using the WST-1 proliferation assay (Roche
Molecular Biochemicals, Penzberg, Germany). This assay measures the activity of
the mitochondrial succinate-tetrazolium reductase system. In living cells, the WST-1
substance is converted to a dye which can be detected by an ELISA reader. For this
assay, cells were seeded in a 96-well plate (1000 cells/ well), and after 3-4 days they
were stimulated. After 24 hours, the WST-1 reagent was added to a final dilution
1:10, and after 2 hours incubation, the plate was measured with the ELISA reader at
450 nm.
Cell viability was determined by acridine orange/ ethidium bromide staining. Acridine
orange, but not ethidium bromide, can be incorporated into living cells with intact cell
membranes and the cell nucleus will stain green. If the cell is dead, ethidium bromide
will reach the nucleus bypassing the destroyed cell membrane, intercalate into the
DNA and stain the cell nucleus red. A mix of equal volumes of cell suspension and
1:1 acridine orange/ethidium bromide was placed on a Neubauer chamber.
Examination was conducted under UV light. The cell viability was determined as the
percentage of green (= live cells) in the total number of cells seen on each chamber
area.
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2.6. Gene expression studies
2.6.1. RNA extraction
Tissue fragments of normal or adenomatous pituitary was embedded in 800 µl
Solution D and homogenized using the Ultra-TURRAX T8 (IKA Labortechnik)
homogenizer. Solution D was composed by guanidine thiocyanate and beta-
mercaptoethanol which by inhibiting the RNases prevents a possible RNA
degradation. To the homogenized tissue, 80 µl (1/10 of the initial Solution D volume)
sodium acetate was added to precipitate the genomic DNA, followed by 800 µl
phenol and 160 µl Chloroform: Isoamylalcohol (49:1). After 15 min incubation in ice,
the solution was centrifuged for 30 min at maximum speed (12000 rpm) at 4°C. At
this stage, due to the phenol, two phases are clearly visible, separated by a thin zone
containing the precipitated genomic DNA. The lower phase contains the phenol-
soluble proteins and cell rests. The upper phase, containing the RNA, was carefully
collected, taking special care not to be mixed with the genomic DNA- containing the
intermediate zone, and was transferred to a new Eppendorf tube. Isopropanol was
added in a volume equal to the upper phase, and the solution was incubated at –
20°C for 2-12 hours to allow the complete RNA precipitation. After 30 min
centrifugation, the supernatant was discarded, the pellet was washed with ice-cold
70% ethanol, and the solution was centrifuged for another 30 min. Next the ethanol
was carefully discarded, the pellet was let to completely air dry, before being
dissolved in 20-100 µl water supplemented with 0.1% (v/v) DEPC. DEPC inactivates
RNases, thus protecting RNA against degradation.
RNA from cell culture was extracted as described above. After removing the cell
culture medium and washing it with PBS, an appropriate amount of solution D was
added in the petri-dish or well (usually it is 1 ml solution D per petri-dish, 800 µl per
well in a 6-well plate and 200 µl per well in a 48-well plate).
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When enough material was obtained, each RNA sample was aliquoted, keeping one
aliquot in -20°C for current use, and the remaining at -80°C for long term storage.
The concentration and cleanliness of each RNA sample was determined using a
spectrophotometer (Ultrospec II, Pharmacia). Nucleic acids have an absorption
maximum at 260 nm, while for proteins the value reaches 280 nm. The ratio A260/A280
gives information about the quality of the RNA preparation, i.e. if it is free from
proteins and phenol rests. The optimal value for a very clean RNA solution lies
between 1.9 and 2.0. RNA concentration is calculated using the following formula:
A260 . 40 . 60 = χ µg/µl, where 40 is the concentration in µg/µl of RNA giving A260
value equal to 1, and 60 is the dilution in which the RNA is measured (1µl RNA
solution + 59µl DEPC water)
2.6.2. Reverse transcriptase – polymerase chain reaction (RT-PCR)
1 µg of RNA was incubated with 2mM dNTP mix, 2µl random primers
(Hexanucleotide Mix), 10mM dithiothreitol (DTT) and 200 U reverse transcriptase
(SuperScript II) all diluted in 1x First Strand buffer, at 45°C for 1 hour. The reaction is
inactivated by boiling at 95°C for 5 min. The cDNA produced was stored at -20°C.
For the PCR reaction 2 µl cDNA were added in a reaction mixture containing:
3 µl      10x PCR buffer
1.8 µl   25mM MgCl2
3 µl      2mM dNTP Mix
1 µl      amplification primer 1; 10 pmol/µl
1 µl      amplification primer 2; 10 pmol/µl
0.3 µl   Thermus aquaticus (Taq) DNA polymerase
17.9 µl autoclaved, distilled water
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The PCR reaction parameters were: denaturation at 95°C for 1 min, annealing at 55-
65°C for 1 min, polymerization at  72°C for 1 min, for 35-40 cycles. In every PCR
reaction, cDNA from normal human pituitary was used as positive control and
reaction in absence of template as negative control. To ensure that the RNA samples
were not contaminated by genomic DNA, PCR reaction was carried for a
housekeeping gene (beta-actin or GAPDH) using as template RNA sample which
had not been reverse-transcribed.
After each reaction, the products were separated in a 1.2-1.5% agarose gel
depending on the size of the product (1.2% for 400-1000 bp, 1.5% for 200-400 bp)
and visualized by ethidium bromide under UV light.  Electrophoresis took place in 1x
TBE buffer for 15-20 min at 80 V. The 1kb Plus DNA marker was used to determine
the fragment size.
The primers used are listed in Table 4, with their sequences, annealing temperature
and predicted product size. The sequence of each was checked using the NCBI
BLAST program, to exclude the possibility of a sequence similarity with genes other
than the one under investigation. All primers were synthesised by MWG Biotech,
were reconstituted with autoclaved distilled water to reach a concentration of 100 µM,
and were stored at -20°C. The annealing temperature for each pair of primers was
determined by PCR in a range of 55, 60, and 65°C using cDNA from normal human
pituitary as template. The optimum temperature was the one that yielded an intense
signal with no secondary amplification fragments.
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Table. 4. List of primers used.
Name Sequence (5’-3’) Tma) Fragment (bp) b)
beta-actin-s human
beta-actin-a human
ACG GGG TCA CCC ACA CTG TGC
CTA GAA GCA TTT GCG GTG GAC GAT G
60 660
GAPDH-s rat
GAPDH-a rat
ATG GTG AAG GTC GGT GTG AAC G
GTT GTC ATG GAT GAC CTT GGC
60 495
SF1-s
SF1-a
GCA TCT TGG GCT GCC TGC AG
CCT TGC CGT GCT GGA CCT GG
71 230
hTlr 4-s
hTlr 4-a
ACA GAA GCT GGT GGC TGT G
TCT TTA AAT GCA CCT GGT TGG
59 290
mTlr 4-s
mTlr 4-a
GGG TCA AGG AAC AGA AGC AG
GCT CAT TTC TCA CCC AGT CC
60 264
Pit-s
Pit-a
AGT GCT GCC GAG TGT CTA CCA
TTT CTT TTC CTT TCA TTT GCT
59 560
a) annealing temperature; b) size of PCR product.
2.6.3. In situ hybridization
2.6.3.1. Principle.
In situ hybridization is a method of localising and detecting specific mRNA sequences
in morphologically preserved tissues sections or cell preparations by hybridizing the
complimentary strand of a nucleotide probe to the sequence of interest.
The first step of in situ hybridization is the selection of a probe type. Several different
probes can be used, such as double strand DNA (dsDNA), single stranded DNA
(ssDNA), single stranded complimentary RNA (sscRNA), and synthetic
oligonucleotides.
In order to observe where the probe had hybridized (bound) within tissue section or
within cells and thus to determine where target mRNA is localised, an easily
detectable substance or "label" has to be attached to the probe before hybridization.
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Classically oligonucleotide probes are either 5' or 3' end-labeled or 3' tailed, with
modified nucleotides that have a "label" attached that can be detected after the probe
has hybridized to its target. With end-labeling a single modified ddNTP (that
incorporates the label) is added to either the 5' or the 3' end of the molecule
enzymatically or during probe synthesis. 3' tailing involves addition of a tail (on
average 5-50 nucleotides long of modified dNTPs depending on the method used)
using the enzyme terminal transferase (TdT).
Traditionally oligonucleotide probes have been radiolabeled. 3H, 33P or 35S are the
most commonly used radioisotopes. Radiolabeled probes are visualized by exposure
of the tissue section or cells (to which the labeled oligonucleotide has be hybridized)
against photographic film which is then developed
Instead of using photographic film to detect the probe within the tissue section, the
slide containing the section of interest may also be dipped into a photographic
emulsion which is allowed to dry. The slide is stored in the dark at -80C to allow the
slide emulsion to become exposed. After the incubation period, the slides are then
developed in the same way as normal photographic film. Thus you view the section
or cells of interest through the developed photographic emulsion and the black silver
grains indicate the sites of the labeled transcripts. This is particularly useful for
investigating gene expression on a cell by cell level.
It is important that the probe reaches the target, which is the mRNA of the target
gene located in sample. With a tissue section this may not be much of a problem ,
but in whole cells or even in whole organisms then there are cell membranes which
have to be crossed. The act of fixation results in cross-linking of proteins, which once
again may present an obstacle to good infiltration of the probe, and finally mRNA
sequences are often surrounded by proteins which may mask the target sequence.
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Three common reagents used to permeabilize tissue are HCl, detergents (Triton or
SDS) and Proteinase K.
The composition of the hybridization solution is critical in controlling the efficiency of
the hybridization process. Hybridization depends on the ability of the oligonucleotide
to anneal to a complementary mRNA strand just below its melting point (Tm). The
value of the Tm is the temperature at which half of the oligonucleotide is present in a
single stranded form.
The factors that influence the hybridization of the oligonucleotide probe to the target
mRNA are: temperature, pH, monovalent cation concentration, presence of organic
solvents. The following is a typical hybridization solution with a hybridization
temperature of around 37 C and an overnight incubation period- Dextran sulphate,
formamide and DTT (dithiothreitol), SSC (NaCl + Sodium citrate) and EDTA.
Other components are added to decrease the chance of nonspecific binding of the
oligonucleotide probe and include: ssDNA, tRNA acts as a carrier RNA, polyA,
Denhardts solution.
Following hybridization the material is washed to remove unbound probe or probe
which has loosely bound to imperfectly matched sequences. Washing should be
carried out at or close to the stringency condition at which the hybridization takes
place with a final low stringency wash.
2.6.3.2. Protocol for cryostat sections
ISH was performed with shock-frozen pituitary and adenoma, which was cut into 8-
µm sections were thaw-mounted onto sterile poly-L-lysine-coated slides, fixed in 4%
phosphate-buffered paraformaldehyde and stored in 96% ethanol at 4°C until use.
hTlr4 oligodeoxynucleotides pos. 308 (ODN; MWG Biotech, Ebersberg, Germany)
complementary to coding parts of Tlr4 mRNA were 3'-end labeled with [α33P]-dATP
(NEN Life Science Inc., Boston, MA) by terminal transferase (Roche Molecular
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Diagnostics, Mannheim, Germany). The sequences are 5’ AAG CTC AGG TCC AGG
TTC TTG GTT GAG AAG GGG AGG TGG TCG GGG 3’. After rehydratation in PBS
and a passage into 0,25% acetic anhydarate in 0,1 M triethanolamine-HCl pH 8,0/
0,9% NaCl for 10 min, sections were dehydrate in ethanol , 2 min 70 % ethanol, 2
min 96% ethanol and finally air dried. Each section was hybridizate with a solution
containing 50,000-200,000 cpm of radioactive probe, 50 % deionized formamide, 4x
SSC, 10% dextrane sulfate, 100 µg/ml polyadenylic acid, 5X Denhardts, 25 mM
sodium phosphate, pH 7.0 0,1 mM. After washing in 1xSSC for 10 min at room
temperature (rt), 1xSCC 30 min at 55 C, 1xSCC, 0,1xSCC, for 1 min each at room
temperature  and dehydratation in ethanol sections were dipped in Ilford K5
photoemulsion (Ilford, Dreieich, Germany) and developed after 28 days and
counterstained with toluidine blue. For negative control, a 100-fold excess of non-
labeled ODN was added to the radioactive probe and applied to the adjacent section
on the same slide. Human tonsils served as positive control.
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2.7. Protein studies
2.7.1. Immunohistochemistry
2.7.1.1. Principle
In order to visualise the protein distribution and intensity of expression in the normal
cellular and tissue environment, the method of immunohistochemistry was employed.
Specific antibodies (primary antibodies) are used to identify the protein of interest.
This antigen-antibody binding is followed by a series of immunological interactions,
which lead to the enzymatic reaction that will allow the visualisation of the signal.
After the primary antibody has attached to its epitope, it is linked to a secondary
antibody, that can recognise and therefore bind to the epitopes of the host animal in
which the primary antibody was raised; i.e. when the primary antibody is mouse
monoclonal the secondary antibody is anti-mouse and so on. The secondary
antibody is then linked to the enzymatic complex that will catalyze the chromogen
used and visualise the signal. One system used here is the avidin-biotin system, in
which the secondary antibody is conjugated to biotin beads, which can bind to the
avidin-enzyme complex. The enzyme can be peroxidase or alkaline phosphatase.
2.7.1.2. Primary antibodies
The primary antibodies and dilutions used are given in Table 5. Each antibody was
tested and optimised on control tissue, which was usually human normal tonsil. The
standard testing dilution range was 1:50 to 1:2000.
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Table.5. List of the primary antibodies used in this group of studies.
Antibody Source Host Dilution
Tlr4  Zymed Laboratories Inc., San
Francisco, CA
rabbit a 1:200
Human TSH Immunotech (Marseille, France) mouse b 1:500-800
Human FSH Immunotech (Marseille, France) mouse b 1:500-800
Human LH Immunotech (Marseille, France) mouse b 1:500-800
Human Alpha-
Subunit
Immunotech (Marseille, France) mouse b 1:500
Human PRL Immunotech (Marseille, France) mouse b 1:400
Human ACTH DAKO (Glostrup, Denmark) mouse b 1:100
Human GH Gift from Dr C. J. Strasburger
(Medizinische Klinik, Munich,
Germany)
mouse b 1:800
a) polyclonal, b) monoclonal
2.7.1.3. Protocol for cryostat sections
Frozen normal and adenomatous pituitary tissues were cut in a cryostat (Leica
CM3050 S), in 8 µm thick sections. The slides were fixed in 4% freshly prepared ice
cold PFA, dehydrated and stored in 96% ethanol, at +4°C. At the time of the
experiments, sections were briefly incubated in TBS for 5 min, followed by 30 min
blocking. Blocking was performed using serum from the same animal species in
which the secondary antibody was generated; in our case blocking solutions were
consisting of horse or goat serum diluted 1:10 in TBS. After blocking the endogenous
peroxidase activity with 1% H2O2 diluted in TBS for 15 min, sections were incubated
overnight with the primary antibody at 4°C. Then, after washing three times with TBS,
5 min each, sections were incubated for 30 min with the secondary antibody at room
temperature, and after 3 more washings, with the ABC complex for another 30 min.
The ABC was prepared in saline-free tris-based buffer (Tris buffer) at least 30 min
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prior to use, to allow complex formation. After washing three times in TBS, slides
were immersed in freshly prepared DAB (1 mg/ml) supplemented with 0.01%
hydrogen peroxide. Because DAB is light-sensitive, the reaction was carried on in
semi-darkness, and the reagent was covered with aluminum foil during the
experiment. The time of incubation in DAB varied and was determined for each
primary antibody separately. The optimal time was the one which gave the strongest
expected signal with the lowest possible background.
A variation of the method made use of ABC linked to alkaline phosphatase (ABC-AP)
and in that case, colour was developed using the Vector Red kit. Levamisole (10
mM) was added to the reaction mixture to block the endogenous alkaline
phosphatase activity. This method was used for immunohistochemical determine
action of hormones in each tumour.
After the development of a signal, slides were washed 3 times in TBS and
counterstained with toluidine-blue, which stains the cell nuclei pale blue, affording a
good view of the tissue organisation. Excess colour was removed by immersing the
slides in 70% ethanol supplemented with acetic acid, and sections were dehydrated,
fixed in xylol and coverslipped using Entellan. Evaluation of immunohistochemistry
was performed using the Axioscop II microscope (Zeiss).
Double IHC for Tlr4 and hormone co-localization was conducted by performing first
IHC for Tlr4; visualising immunoreactivity with DAB, and then IHC for the hormone,
visualising immunoreactivity with Vector Red (Vector). All the buffers used were
phosphate-free. Endogenous alkaline phosphatase activity was blocked by adding 10
mmol/L levamisole (Sigma, St. Louis, MO, USA) to the Vector Red substrate.
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2.8 Transfection studies
2.8.1. Plasmid preparation
The plasmid used in this study was a vector expressing the luciferase gene under the
control of 770 bp of the rat POMC promoter (Liu et al., 1992).
Competent bacteria (i.e. bacteria pre-treated in such way that they posses pores and
can therefore incorporate a plasmid easily), were transformed, left on agar containing
ampicillin at 37°C to grow overnight, and stored at +4°C. A colony was selected from
each plate and left in 250ml LB medium containing 50µg/µl ampicillin overnight at
37°C. Plasmid preparation was performed using the QIAGEN plasmid purification
system.
2.8.2. Cell transfection
Cell transfection was performed on confluent AtT-20 cells grown in a 24-well plate,
using Lipofectamine as follows: 500ng of POMC-Luc was mixed with 2,5µl/well of
Lipofectamine in OPTIMEM1 medium, and incubated at room temperature for 45
min. During this time, the Lipofectamine neutralises the plasmid DNA and surrounds
it by lipid molecules. Cells were washed twice with OPTIMEM1, and transfected with
plasmid for 6 hours. At this point, the lipid molecules of the lipofectamine will fuse
with the cell membrane, emptying the plasmid content into the cytoplasm. Next, the
transfected cells were supplemented with fresh DMEM containing 10% FCS and left
for 18 hours to recover before stimulating with LPS for 6, 12, 18 or 24 hours.
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2.8.3. Reporter assay
To determine the levels of POMC driven luciferase expression after stimulation with
LPS, a luciferase reporter assay was employed. Luciferase is an enzyme found in the
Photinus pyrallis, the common firefly. Luciferase emits light in the presence of
luciferin and ATP, which can be detected at 562nm wavelength.
After washing once with PBS the cells were lysed using the reporter lysis buffer and
scraped. The lysates were transferred into Eppendorf tubes and centrifuged briefly.
The supernatants were collected to be assayed as follows: 50µl supernatant was
mixed with equal amount of ATP-containing Luciferase-assay buffer, and luciferase
activity was measured in a Berthold luminometer, using 4 mg/ml luciferin as
substrate. The experiments were carried out 6 times.
2.9. Stimulation and measurement of IL-6 in pituitary adenoma cell cultures
Before the measurement of basal or stimulated IL-6 production in human pituitary
adenoma cell cultures, an initial culture medium was removed and the cells were
washed twice with PBS. Adenoma cell cultures were then cultivated for an additional
24 hrs in serum-reduced (2% FCS) culture medium with and without (basal IL-6
production) the different stimuli as indicated. Human IL-6 was measured in the cell
culture supernatants by ELISA (R&D Systems, Wiesbaden, Germany) according to
the manufacturer’s instructions and as previously described (Pereda et al., 2000).
2.10. Hormone secretion studies
Hormones were measured by direct radioimmunassay (RIA). RIA is an method for
measuring the quantity of indicator molecules, labelled with a radioisotope by
counting radioactive decay events in a scintillation counter. A fixed quantity of
antibody is attached to a solid support. The immobilised antibody will bind a finite
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portion of added radiolabeled indicator antigen. How much antigen binds depends on
the antigen concentration and the affinity of the antibody for the antigen. In the assay,
the test solution of unknown antigen concentrations of unlabeled antigen for their
ability to inhibit competitively the binding of the radiolabeled indicator antigen (tracer)
to the immobilised antibody. The greater the content of competing antigen in the test
or standard solution, the less a radiolabeled indicator antigen is bound. The results
for the standard solutions of a known antigen concentration are used to derive an
inhibition curve as function of antigen concentration, from which the concentration in
the test sample can be calculated.
ACTH in medium was directly measured with the use of standards diluted in DMEM:
A N-terminal-specific antibody was generated as previously described (Stalla et al.,
1986; Stalla et al., 1989).
 Rat (r) and rPRL in the medium were directly measured with reagents kindly
provided by the National Hormone and Pituitary Program (Baltimore, MD).
2.11. Statistics
Statistics to determine the significance of LPS treatment on POMC promoter activity,
on cell proliferation and on IL-6 expression, were performed using a t-test.
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3. RESULTS
3.1. Expression of Tlr4 in pituitary cell lines
In clonal mouse, rat and human pituitary tumour cell lines Tlr4 synthesis was studied
using RT-PCR with primers specific for mouse/rat or human Tlr4. Murine and human
Tlr4 mRNA was detected in RNA preparations from a mouse spleen and human
tonsils, which were used as positive controls (figure 3A, 3B). In rodent cell lines,
apart from FS-like TtT/GF cells, Tlr4 synthesis was found in corticotroph mouse
AtT20 cells, but not in gonadotroph mouse αT3-1 and lactosomatotroph rat GH3
cells. In human cell lines, production of Tlr4 mRNA was detected in FS-like PDFS
cells, in hormone-inactive-like HP75 cells and breast cancer cell line MCF 7. The
results show that not only FS cell lines but also some, but not all, epithelial pituitary
tumour cell lines synthesize Tlr4. Expression of Tlr4 in MCF7 cells indicates, that this
receptor may also has relevance in other endocrine tumour tissues.
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Fig. 3. Tlr4 gene expression in mouse/rat as determined by RT-PCR (A) and human
pituitary epithelial cell lines and breast cancer epithelial cell line (B). Human tonsils
was used as positive control in B. The predicted amplifications products (264bp for
murine Tlr4 and 290 bp for human Tlr4) are not present in negative control. As
negative control was used water instead of template.
3.2. Expression of Tlr4 in normal and tumoural human pituitary
In 3 normal human pituitaries and in 67 pituitary adenomas (table 6), Tlr4 mRNA
expression was determined by ISH and protein expression was studied by IHC. In
addition, in 3 of 3 normal pituitaries and in 25 of 67 adenomas, Tlr4 mRNA
expression was investigated by RT-PCR.
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Tlr4 mRNA expression was found in normal pituitaries by RT-PCR (figure 4) and by
ISH (pictures not shown).
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Fig. 4. Tlr 4 gene expression in 3 normal pituitaries by RT-PCR (first panel). Positive
control was a human tonsil. The predicted amplifications product 290 bp for Tlr4 is
not present in negative control. As negative control was used water instead of
template. Β-actin in the same set of pituitaries (second panel).
By ICH in all 3 normal pituitaries, scattered expression of Tlr4 protein was observed
in the anterior pituitary and  highly expressed in posterior lobe (figure 5 A, B).
Double-immunocytochemical studies revealed Tlr4 expression in all types of
endocrine cells, but only very few hormone-producing cells were co-expressing Tlr4
(figures 5C, D; 6 A, B, C, D).
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Fig. 5. Tlr4 protein expression in human pituitary as determined by
immunohistochemistry. A. Tlr4 protein expression in anterior pituitary;
immunopositive cells pointed with black arrows. B. Strong immunoreactivity for Tlr4
protein (brown) in posterior lobe. Tlr4 colocalization with ACTH (C) and with LH (D)
(black arrows) in normal anterior pituitary by double immunohistochemistry. All
sections are counterstained with toluidine blue. Insets in pictures A, B- specificity of
immunoreactivity using preabsorbed serum, inset in picture (C)-ACTH
immunostaining (red) and in (D)-LH (red) immunostaining without antibody for Tlr4.
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Fig. 6. Tlr4 protein expression in human anterior pituitary by double
immunohistochemistry. Tlr4 colocalization with TSH (A), FSH (B), GH (C) and PRL
(D) (black arrows) in normal anterior pituitary. All sections are counterstained with
toluidine blue. Inset in (A)-TSH staining (red), (B)-FSH staining (red),(C)-GH staining
and (D)- PRL staining without Tlr4 antibody.
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ISH and IHC for Tlr4 were performed in all 67 adenomas (table 6). Adenomas which
show Tlr4 protein expression on pituitary tumour cells by IHC were considered to
represent Tlr4-positive pituitary tumours since only Tlr4 protein-expressing
adenomas would functionally respond to LPS (or other Tlr4 ligands). Tlr4 protein
expression was found in 26 out of 67 adenomas (table 6). In the majority of Tlr4-
positive adenomas found (21 out of 26 cases), scattered Tlr4 protein expression in
less than 5 % of all adenoma cells was observed whereas only a few adenomas
showed higher Tlr4 immunopositivity (figures 8C and D). ISH studies on cellular Tlr4
mRNA showed only a very faint expression of Tlr4 transcripts (figures 8A and B)
indicating a low synthesis- and turnover-rate of Tlr4. This may explain why only in 15
out of 26 Tlr4-immunopositive adenomas Tlr4 mRNA could be found by ISH. Despite
the presence of Tlr4 protein, no Tlr4 mRNA expression could be detected in 11 of 26
adenomas. Interestingly, Tlr4 mRNA could be found in 8 adenomas, which did not
express Tlr4 protein indicating disturbances at the level of transcription or protein
processing. Considerable discrepancies were also observed between Tlr4 mRNA
expression detected by PCR and Tlr4 protein expression. 14 adenomas in which Tlr4
mRNA was found by PCR did not express Tlr4 protein at adenoma cell level,
suggesting that by PCR also Tlr4 from white blood cells may have been amplified in
adenoma tissue fragments contaminated with coagulated blood.
In summary, Tlr4 protein could be detected in adenoma cells in 26 out of 67 pituitary
adenomas (table 6). However, even in Tlr4-positiv adenomas, only a subset of cells
represents a possible target of LPS. Tlr4-producing tumours were found in all types
of pituitary adenomas (table 7) indicating no prevalent expression of Tlr4 in
subgroups of hormone-producing or hormone-inactive pituitary tumours.
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Fig. 7. Tlr.4 gene expression in 10 representative out of 25 pituitary adenomas. Acro:
acromegaly associated adenomas; Cush: Cushing’s associated adenomas; HI:
hormone inactive adenomas. A human tonsil was used as positive control. As
negative control was used water instead of template.
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Tab. 6. Expression Tlr4 in pituitary adenomas (list of the 67 tumours).
Description gender age PCR ISH ICH a) evaluation
1. Acro m 27 - - -
2. Acro f 28 + + +
3. Acro m 50 + - ++ +
4. Acro m ? + - - -
5. Acro f 37 - - -
6. Acro f 53 - - -
7. Acro m 31 + + +
8. Acro m 29 ++ - - -
9. Acro m 63 + + +
10. Acro f 71 - + +
11. Acro f 41 - + - -
12. Acro f 38 - - -
13. Acro m 31 - - - -
14. Acro m 30 - - -
15. Acro f 51 - + +
16. Acro m 67 - ++ +
17. Acro m 42 - - -
18. Acro f 76 ++ - + +
19. Cush m 23 + + + +
20. Cush f 22 + + +
21. Cush m 32 + + + +
22. Cush f 23 + + +
23. Cush m 44 - - -
24. Cush m 14 + - - -
25. Cush m 31 + + - -
26. Cush f 52 ++ - - -
27. Cush m 59 - + +
28. Cush m 20 ++ - - -
29. HI m 80 +++ + ++ +
30. HI f 51 + ++ +
31. HI m 48 + - -
32. HI f 65 +++ - - -
33. HI m 46 + + +
34. HI m 49 + + +
35. HI m 34 - - -
36. HI m 76 - - -
37. HI m 39 ++ - - -
38. HI m 47 - + +
39. HI m 59 - - -
40. HI f 51 + ++ +
41. HI f 30 + - -
42. HI m 52 ++ - - -
43. HI m 49 + - - -
44. HI m 53 - - - -
45. HI m 76 - - -
46. HI m 78 + - - -
47. HI m 60 - + +
48. HI f 61 - - -
49. HI f 59 - + +
50. HI m 35 + - - -
51. HI f 70 - - -
52. HI f 52 - - -
53. HI m 45 - - -
54. PRL m 34 - - -
55. PRL f 41 + - + +
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56. PRL m 42 + - -
57. PRL m 41 - - + +
58. PRL m 43 - + - -
59. PRL m 38 + - -
60. PRL f 18 + + - -
61. PRL f 26 - - -
62. PRL m 30 + + +
63. PRL m 43 + + +
64. PRL m 30 - - -
65. PRL f 27 - - - -
66. TSH m 43 + - -
67. TSH f 56 + + +
a) Tlr4 immunoreactivity was taken as standard for the final evaluation and was
determined by two independent investigators and categorized in 3 classes: (-) no Tlr4
ir, (+) weak ir (less than 10 % adenoma cells were positive for Tlr4), (++) moderate ir
(10 to 30 % were positive).
Tab. 7. Overview for Tlr4 expression in pituitary adenomas.
Tumour type Number of tumours Tlr4-positive adenomas
HIA 25 8 (32%)
SA 18 8 (44%)
LA 12 4 (33%)
CA 10 5 (50%)
TA 2 1 (50%)
Total 67 26 (39%)
Abbreviations: CA, corticotroph adenomas; HIA, hormone-inactive adenomas; LA,
lactotroph adenomas; SA, somatotroph adenomas; TA, thyreotroph adenomas.
51
Fig. 8. Tlr4 mRNA (determined by in situ hybridization) and protein expression
(immunohistochemistry) in human pituitary adenomas. A and B. weak Tlr4 mRNA
expression, determined by ISH (silver grains). C. Moderate immunoreactivity for Tlr4
protein (brown) in Cushing tumour. D. Weak immunoreactivity for Tlr4 protein (brown)
in a prolactinoma. Insets in A and B control for signal specificity using an excess of
unlabeled oligonucleotides. Insets in C and D specificity of immunoreactivity using
preabsorbed serum.
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3.3. Effect of LPS on proliferation in AtT20 and GH3 cells
In Tlr4-positive AtT20 cells and in Tlr4-negative GH3 cells direct effects of LPS on
cell growth were studied. LPS dose-dependently inhibited the proliferation of AtT20
cells. Significant inhibition was already observed at 100 ng/ml LPS and maximum
inhibitory effects were obtained after treatment of AtT20 cells with 1 µg/ml LPS(figure
9). On GH3 cells LPS did not reveal any effect on the cell proliferation (data not
shown).
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Fig. 9. LPS inhibits cell proliferation in AtT20 cells. AtT20 cells were treated with LPS
for 24 hours. Proliferation was measured by WST-1. **or p=0.003, * p=0,017 in
comparison to basal.
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3.4. Effect of LPS on hormone production in AtT20 and GH3 cells
As for proliferation, LPS effects on hormone synthesis and release were
comparatively studied in atT20 cells and GH3 cells. In AtT20 cells transiently
transfected with a POMC-luciferase (POMC-LUC) reporter plasmid, forskolin
significantly enhanced the luciferase activity whereas LPS did not induce POMC
transcription (figure 10). Forskolin as a stimulator of adenyl-cyclase activates the
cAMP signal trasduction pathway, which, in turn mediates hormonal secretion in
AtT20 cells (Lamas et al., 1997). The release of ACTH was also not affected after
short (6h)- or long (24h)-term treatment with different doses of LPS. No effect of LPS
on GH or PRL secretion was also observed in GH3 cells (data not shown).
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Fig. 10. In AtT-20 cells transfected with 500 ng POMC-Luc stimulation with LPS 10,
100 ng/ml, 1µg/ml and Forskolin (Forsk) for 6 hours resulted only in increase of
forskolin induced luciferase activity. *** p< 0,001 in comparison to basal activity.
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3.5. Effect of LPS on IL-6 secretion by pituitary adenoma cell cultures
The effects of LPS on growth of pituitary tumours are difficult to investigate, since
pituitary adenoma cells grow very slowly in culture. Therefore the effect of LPS on IL-
6 production was studied in pituitary adenoma cell cultures, since pituitary tumor cells
produce IL-6 in the majority of pituitary adenomas. Among the11 pituitary adenomas,
from which cell cultures were established, 3 tumours (1 Tlr4-positive and 2 Tlr4-
negative adenomas) did not produce detectable amounts of basal IL-6 (table 8).
Tab. 8. Effect of LPS on IL-6 secretion in Tlr4-positive and -negative pituitary
adenomas.
IL-6 secretion (pg/ml)Tumour type
basal LPS a
Tlr4
HI
HI
HI
HI
SA
HI
HI
HI
HI
HI
SA
n.d.
n.d.
n.d.
1140±58
15,1±2,0
18,5±2,3
278±41
78±12
471±25
211±41
714±28
1409±315b
n.d.
n.d.
7160±1064b
206±35b
1447±254b
1519±49b
98±18
537±65
229±30
712±50
yes
no
no
yes
yes
yes
yes
no
no
no
no
a) IL-6 values after 24h stimulation with 1 µg/ml LPS; b) p<0.01. n.d., not detectable
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 Variable basal IL-6 production ranging from 78 to 1140 pg/ml was measured in 8
adenomas, 4 of which were Tlr4-positive. LPS strongly stimulated IL-6 release in all
cell cultures from Tlr4-positive adenomas even in the tumour cell culture in which no
basal IL-6 secretion was detectable. In contrast, in adenoma cultures of Tlr4-
negative adenomas, LPS had no effect on IL-6 secretion in IL-6-producing adenomas
and could not induce IL-6 production in adenomas with undetectable basal IL-6.
Dose-response studies (1ng/ml to 10 µg/ml LPS) showed that the maximal IL-6
stimulation was achieved at 1 µg/ml LPS (figure 11). Dexamethasone was a potent
inhibitor of LPS-induced IL-6 secretion in all LPS-responsive adenomas. In dose-
response studies (1 nM to 10 µM), 100 nM dexamethasone completely blocked the
IL-6 secretion stimulated by 1 µg/ml LPS (figure 11).
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 Fig. 11. LPS-induced IL-6 secretion and its inhibition by dexamethasone in a
nonfunctioning pituitary adenoma cell culture. * p<0,05; ** p<0,01 vs. basal IL-6. #
p<0,05; ## p<0,01 vs. IL-6 secretion in cells stimulated with 1000ng/ml LPS.
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In 3 adenomas, in which LPS stimulated the IL-6 secretion, the effect of the p38α
MAP kinase inhibitor SB203580 (20 µM) was studied. In all tumour cell cultures,
SB203580 suppressed the LPS-induced IL-6 production. This suggests that similar to
FS pituitary cells, the p38α MAP kinase pathway is involved in LPS-induced IL-6
secretion in pituitary adenomas.
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Fig. 12. Suppression of LPS induced IL-6 secretion by the p38α MAP kinase inhibitor
SB 203580 in a somatotorph adenoma cell culture. * p<0,05; ** p<0,01 vs. basal IL-6;
# p<0,05; ## p<0,01 vs. corresponding IL-6 secretion by cells without SB treatment.
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3.6. Effect of paclitaxel (taxol) on the cell proliferation and hormone secretion
in AtT20 cells.
Not only LPS, but also the chemotherapeutical drug taxol is supposed to act through
Tlr4, at least in rodent cells. Paclitaxel (Taxol) inhibited the proliferation of AtT20 cells
in dosage-dependent manner. In contrast to LPS, apoptotic changes as cell rounded
and detachment were additionally observed after 24 h of treatment with taxol
(Fig.13). Short-term (4 h) and long-term (24 h) treatment of AtT20 cells with taxol
(10nM to 10 µM) did not significantly alter ACTH secretion (data not shown). The
proliferation and cell morphology of Tlr4 negative GH3 cells was not affected by taxol
treatment (data not shown).
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Fig.13. Effect of paclitaxel (taxol) on the cell proliferation in AtT20. AtT20 cells were
treated with taxol for 24 hours. Proliferation was measured by WST-1. *** p=0.001, *
p=0,013 in comparison to basal. For basal, 10 nM, 1µM concentration of taxol were
presented morphological images, which showed cellular rounding up, induced by 1
µM taxol.
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4. DISCUSSION
In the present work it has been shown for the first time that the Toll-like receptor 4
which represents the major signal transducer of bacterial lipopolysaccharide, is
expressed not only in folliculostellate cells of the anterior pituitary but also in small
subsets of all endocrine pituitary cells. Moreover, heterogeneous Tlr4 expression was
found in 26 out of 67 pituitary tumours studied. It could also be demonstrated that the
Tlr4 is functionally active in the subpopulation of Tlr4-positive adenomas and in a
Tlr4-expressing pituitary cell line. This suggests that during transient or chronic
bacterial infectious and inflammatory processes, circulating LPS could affect the
progression of Tlr4-positive pituitary adenomas.
Only few years ago, Tlr4 has been identified as receptor and signal transducer of
lipopolysaccharides, the endotoxins of gram-negative bacteria (Medzhitov et al.,
1997). Tlr4 belongs to a set of germline-encoded receptors, including also other
members of the Toll-like receptor family which are responsible for the innate
immunity, representing the first line of host defence against infection and malignant
transformation (Asea et al., 2002). Toll-like receptors are abundantly expressed in
immune cells and play an outstanding role in the innate immune response to
bacterial, viral, fungal and protozoan pathogens. TLR signalling can induce the
production of proinflammotory cytokines and upregulate expression of costimulatory
molecules, thereby activate consequently innate and adaptive immune system
(Kaisho and Akira, 2002).
 It was revealed by genetic analysis, that Tlr4 is a critical signal transducer for LPS
(Poltorak et al., 1998), but F protein from respiratory sincytial virus is also acting
through Tlr4 (Kurt-Jones et al., 2000). Interestingly, host origin fibrinogen (Smiley et
al., 2001), the extra domain A of fibronectin (Okamura et al., 2001), heat shock
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protein 60 (Hsp60) (Ohashi et al., 2000) and Hsp70 (Lipsker et al., 2002) all
represent activators of Tlr4. It was found, that human Hsp60 and Hsp70 can activate
NFκB and MAPKs through Tlr2 or Tlr4 (Vabulas et al., 2001). In addition, CD14,
which interacts with Tlr4 and is needed for an optimal response of the Tlr4 to LPS,
recognises apoptotic cells (Devitt et al., 2003). Thus, Tlr4 and its co-receptor CD14
not only recognise exogenous bacterial or viral pathogens, but also respond to
endogenous signals of mammalian eukaryotic cells such as extracellular matrix
components or stress-, apoptosis- or necrosis-associated proteins (Matzinger, 2002).
Therefore, Tlr4 may belong to the factors that provide a molecular basis for recently
developed hypotheses of immune activation, the so-called danger model (Matzinger,
2002) and the surveillance hypothesis (Johnson et al., 2003). In these models it is
thought that the immune system does not only discriminate between self- and
nonself-cells (or antigens of these). It is also activated in response to antigens that
are associated with danger signals released from damaged or stressed cells after
pathogen or toxin exposure, mechanical disruption and so on. Transformed cells of
tumours at advanced stages also produce danger signals. Initially, many tumour cells
do not appear dangerous to immune system, because they grow as healthy cells
without showing changes of extracellular matrix composition or Hsp production which
could both act as danger signals (Kaisho and Akira, 2002). With increasing size the
tumour structure becomes less well organised and disturbances of the extracellular
matrix composition occur. Moreover, cells of poorly vascularised areas within the
tumour are stressed due to insufficient supply with nutrients and oxygen, resulting in
an increased Hsp production. Thus ECM fragments and heat-shock proteins of
progressing tumours may probably activate immune cells through Tlr4 to attack the
growing tumour cells, however the tumour may have developed too far to be brought
under control of the immune system.
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In many organs, epithelial cell layers, in particular those with contact to the
environment, represent a major side of tumourigenesis (Pardoll, 2003). It was shown
that many of these epithelial cells also contain Toll-like receptors, which are thought
to play a role in the induction of local inflammation as part of the host-defense
mechanisms against microbial pathogens. After activation by pathogenic antigens,
epithelial Toll-like receptors like Tlr4 stimulate the production of chemokines and
cytokines in infected epithelial cell layers to induce invasion and migration of immune
cells to the site of pathogenic attack and to induce the inflammatory response. At
present it is not clear, whether Toll receptors like Tlr4 are lost or persist in epithelial
cells after tumoural transformation. In epithelial tumour cell lines, among them the
MCF7 mamma carcinoma cell line, Tlr4 synthesis was detected in the present work.
This indicates that Toll-like receptors may still persist in transformed epithelial cells.
After ligand binding, Tlr4 has been shown to activate the MAP-kinase pathways and
NF-kB which both represent important intracellular signal pathways affecting both
function and proliferation of cells. Thus, the question arises whether increasing levels
of circulating bacterial LPS during transient or chronic infectious processes affect
epithelial tumour cell proliferation and function. However, expression and potential
pathophysiological functions of Toll-like receptors have so far not been studied in
epithelial tumours.
In the present work, synthesis and expression of Tlr4 was studied in normal and
tumoural pituitary epithelial cells. In normal anterior pituitary, scattered Tlr4 protein
expression was found. Some of the cells that are positive for Tlr4 may represent FS
cells which have previously been shown to express this receptor (Lohrer et al., 2000).
However, by double immunohistochemical studies, Tlr4 protein expression was also
detected in all endocrine pituitary cell types of the anterior pituitary but only few
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corticotroph, somatotroph, thyreotroph, gonadotroph and lactotroph cells were
immunopositive for Tlr4. The function of Tlr4 in these small subsets of different
endocrine anterior pituitary cells remains unclear since LPS has so far not been
shown to affect directly the function or growth of normal endocrine pituitary cells. In
vitro and in vivo effects of LPS on anterior pituitary hormone secretion are
predominantly mediated through LPS-induced, immune cell-derived cytokines of the
circulation. However, LPS can also enhance through Tlr4 of FS-cells the production
of intrapituitary IL-6 which can stimulate hormone release in paracrine manner, as
recently demonstrated in a three-dimensional pituitary cell culture model (Gloddek et
al., 2001). But apart from this modulatory role of the Tlr4 of FS cells on immune-
endocrine interactions, other functions of this FS cell receptor may be thinkable
which are based on the danger or the surveillance model. It is known, that the
pregnancy-associated enlargement of the lactotroph cell population is reduced by
apoptosis in the post-partum or post-lactation period. The cell debris of apoptotic
cells is removed by FS cells through phagocytosis. Degraded ECM-products or DNA
of apoptotic cells may probably act through the Tlr4 or other Toll-like receptors of FS
cells to induce phagocytosis. Moreover, folliculostellate Tlr4 may be involved in
hypophysitis, which is characterised by microbial pathogen-induced massive immune
cell filtration of the pituitary and excessive local inflammatory processes, which
damage or destroy hormone producing pituitary cells. An over-reaction of FS cells in
response to pathogens may be responsible for this fatal process. Finally, Tlr4 of FS
cells may play a role in the accumulation of FS cells that has been observed at the
border between normal and tumoural pituitary tissue. Factors derived from the
tumour (e.g. altered components of the extracellular matrix) probably act through Tlr4
to induce migration and/or proliferation of FS cells in the neighbourhood of the
tumour. However, the meaning of FS cell accumulation at the tumour border is
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unclear since it seems that FS cells are not able to eliminate tumour cells or to stop
tumour expansion.
In contrast to anterior pituitary, a strong expression of Tlr4 protein was found in
posterior lobe. Studies in the brain have shown that glial cell types like astrocytes or
oligodendrocytes, but not neurons express Tlr4 and other Toll-like receptors (Bsibsi
et al., 2002). Therefore, in posterior pituitary, Tlr4 may also not be synthesised by the
vasopressin- or oxytocin producing neuronal cells but may be expressed in
pituicytes, which represent an IL-6-producing, microglia-like cell type. The presence
of Tlr4 in pituicytes may well explain the activation of IL-6 in response to the bacterial
endotoxin in posterior pituitary (Spangelo et al., 1994; Hansen et al., 1999; Grinevich
et al., 2003). It was further demonstrated, that IL-6 stimulates vasopressin release in
human and rats (Mastorakos et al., 1994). It needs to be clarified whether during the
course of infectious diseases, pathogens like LPS might influence the water
homeostasis through a mechanism involving Tlr4-induced IL-6 production and
subsequent paracrine vasopressin stimulation within the posterior pituitary.
In pituitary adenomas, a heterogeneous expression of Tlr4 was found. In 39% of the
tumours studied, variable expression of Tlr4 was observed, whereas no receptor
expression was detected in the remaining proportion of tumours. Since pituitary
adenomas are monoclonal in origin, which means that they derive from a single
transformed cell, the Tlr4-negative tumours may originate from a neoplastic Tlr4-
negative pituitary epithelial cell. In Tlr4-positive adenomas the situation is much more
complex, since only small subpopulations of cells express Tlr4. In some tumours 10
to 15% of the cells were positive for Tlr4 protein whereas in the majority of pituitary
adenomas, a scattered Tlr4 expression in less than 5% of all tumour cells was
observed. Based on the monoclonal concept of tumourigenesis, Tlr4-positive
adenomas may have developed from normal Tlr4-negative pituitary epithelial cells
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part of which have acquired the ability to express Tlr4. However, development from
Tlr4-positive epithelial pituitary cells and partial loss of Tlr4 during tumour
progression may also be possible. Since folliculostellate cells are absent (or
extremely rare) in pituitary adenomas, this cell type does not represent the Tlr4-
positive subset of cells within the tumour. At present, the reason for the different
degree of Tlr4 expression or loss of Tlr4 is not yet known. Moreover, Tlr4 absence or
presence was not associated with a particular pituitary adenoma phenotype.
The variability in Tlr4 expression is also reflected at the level of epithelial pituitary
tumour cell lines. As expected, Tlr4 was present in both folliculostellate cell lines
(mouse TtT/GF and human PDFS cells) that have been cloned so far. However, Tlr4
was found only in 2 epithelial tumour cell lines (mouse corticotroph AtT20 cells and
human HP75 cells, which have been cloned from a nonfunctioning adenoma) but not
in lactosomatotroph rat GH3 and in gonadotroph mouse αT3-1 cells. Although the
reason for the different Tlr4 expression in epithelial cell lines is not clear, the different
Tlr4 expression profile allows comparative functional studies on the effects of LPS in
Tlr4-positive and –negative cells.
To study the functionality of Tlr4, investigations of effects of LPS on hormone
secretion are not useful, since it has already been shown that LPS had no direct
effects on hormone synthesis and release which has been confirmed in the present
work (see below). Studies of LPS effects on adenoma cell proliferation are difficult to
perform, because in contrast to rapidly growing pituitary tumour cell lines (see
below), the proliferative index is extremely low in primary cell cultures of pituitary
tumours. Therefore, the functionality of Tlr4 was examined by studying effects of LPS
on the intratumoral IL-6 secretion in primary cell cultures of pituitary tumours. In
contrast to normal pituitary, in which FS-cells exclusively produce IL-6, tumour cells
are the major source of IL-6 in approximately 70 % of adenomas that basally produce
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detectable amounts of IL-6. In the present work, basal production of IL-6 was
measured in 8 out of 11 adenoma cell cultures. In Tlr4-positive adenoma cell
cultures, which released IL-6 under basal conditions, LPS strongly stimulated IL-6
production. In an adenoma, which basally produced no detectable amounts of IL-6,
LPS also induced the release of IL-6. Suppression of LPS-induced IL-6 by the
specific p38αMAP kinase inhibitor SB203580 suggests that similar as in FS cells, the
p38 α MAP kinase signal pathway is involved in Tlr4-induced IL-6 production in
adenoma cells. Moreover, as already observed in FS cells, dexamethasone was a
potent inhibitor of LPS-induced IL-6 production by adenoma cells. These data show
that LPS can strongly stimulate IL-6 production in the subset of Tlr4-positive pituitary
adenomas. IL-6 is an effector of both hormone secretion and growth of pituitary
tumour cells. It has been shown that IL-6 could stimulate the secretion of ACTH in
human corticotroph adenoma cell cultures and could enhance the release of GH in
human somatotroph tumours. Moreover, IL-6 was shown to stimulate the proliferation
of pituitary tumour cells and is therefore considered to represent a tumour
progression factor. Therefore, by stimulating IL-6 in Tlr4-positive pituitary adenomas,
LPS might indirectly contribute to the excessive hormone secretion and may support
tumour expansion.
In epithelial pituitary cell lines, corticotroph AtT20 and nonfunctioning HP75 cells
synthesised Tlr4, whereas lactosomatotroph GH3 and gonadotroph αT3-1cells were
devoid of Tlr4. Tlr4-positive corticotroph AtT20 cells and Tlr4-negative
lactosomatotroph GH3 cells were used to test direct effects of LPS. Both cell lines do
not produce IL-6 under basal conditions or in response to LPS (unpublished
observations) and, therefore, the effects of LPS will not be disturbed by autocrine
acting IL-6. As expected, prolactin and GH secretion were not influenced by LPS in
Tlr4-negative GH3 cells. In Tlr4-positive AtT20 cells, LPS had also no effect on
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POMC mRNA synthesis and ACTH secretion. This confirms previous results from
pituitary monolayer cell cultures in which LPS was not able to affect hormone release
directly. In GH3 cells, proliferation was not affected by LPS but interestingly, growth
of AtT20 cells was inhibited by LPS. It seems that the suppressive effect of LPS on
AtT20 cell proliferation is mediated through a similar, MAP kinase-associated
mechanisms as involved in LPS-induced IL-6 secretion, but this needs to be clarified
in future studies.
The present data indicate that LPS plays different roles in Tlr4-expressing pituitary
adenomas during inflammatory or infectious processes induced by gram-negative
bacteria. On the one hand, circulating LPS could directly act anti-proliferative on Tlr4-
positive pituitary tumour cells, but on the other hand, LPS could support pituitary
adenoma development by stimulating intratumoral IL-6, which will then enhance
growth and hormone secretion of pituitary tumour cells. However, only a small
subpopulation of adenoma cells express Tlr4 in receptor-positive adenomas and only
in this subset of cells LPS would inhibit growth but not influence hormone production.
In contrast, in those Tlr4-positive tumours in which IL-6 is produced and strongly
stimulated by LPS, both hormone production and proliferation of much more cells
would be stimulated by IL-6, since not only Tlr4-positive cells but also other pituitary
adenoma cells in the neighbourhood, would be affected by paracrine-acting IL-6.
Therefore, the stimulatory effects of LPS-induced IL-6 on proliferation and hormone
secretion may dominate upon direct inhibitory growth effects of LPS during gram-
negative bacteria-induced infectious or inflammatory processes.
The situation becomes more complex if it is taken into account that during
inflammation/infection, anti-inflammatory mechanisms are induced to prevent over-
reactions of the activated immune system. In these processes, a rise of anti-
inflammatory-acting glucocorticoids in the circulation is critically involved. Since we
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observed that the synthetic glucocorticoid dexamethasone was counteracting the
effects of LPS on IL-6 secretion in pituitary adenomas, the tumour-promoting
activities of LPS through stimulation of intratumoral IL-6 may be reduced when
glucocorticoid levels increase. Due to the divergent modes of action of LPS and the
counteracting effects of glucocorticoids, at present it remains unclear to which extend
LPS will affect development and pathophysiology of Tlr4-positive pituitary adenomas
in vivo during gram-negative bacteria-induced infection/inflammation.
Infection
ACTH
GH,PRL
LPS
Normal anterior pituitary
immune-endocrine-interaction
IL-6
LPS
transformation
Pituitary tumors
pathophysiological hormone secretion?
tumor progression?
ACTH
GHproliferation
IL-6
No direct effect on hormone
secretion
proliferation
proliferation
Fig. 14 Overview about Tlr4-mediated effects of LPS in normal and tumoural pituitary
cells (details described in the text).
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Tlr4 is not only mediating effects of LPS but has recently been shown to induce
cellular effects in response to compounds associated with ECM degradation. It has
previously been shown that pituitary adenoma development is associated with
alterations of matrix-metalloproteinases (MMP-2, MMP-4) which are extracellular
matrix (ECM) degrading enzymes (Paez et al., 2000). Changes in the ECM
composition of pituitary tumours in comparison to normal pituitary have also been
found. It needs to be clarified whether Tlr4 plays a role in the effects of ECM
components on FS cells and whether alterations of the ECM composition affect IL-6
secretion by similar mechanisms in Tlr4-positive pituitary adenomas.
The Tlr4 is not only a target of microbial pathogens or “danger” signals of mammalian
cells, but may also induce signals in response to pharmacological substances such
as taxol. This plant product (and its derivatives) is one of the most commonly used
and most effective anti-cancer drugs (Crown and O'Leary, 2000). It induces its anti-
tumourigenic effect by stabilising cellular microtubules, which results in an arrest of
the cell cycle at G2/M phase (Schiff and Horwitz, 1980; Horwitz et al., 1986).
Moreover, taxol directly induces apoptosis in several tumour cell lines through
different mechanisms, such as phosphorylation of bcl-2, activation of caspase 8 and
MAPK signal transduction (Lieu et al., 1998; Chadebech et al., 1999; Yamamoto et
al., 1999; Goncalves et al., 2000). In spite of the fact, that the structure of taxol is
quite different from LPS (Wani et al., 1971), it shows immunostimulatory features
(Byrd-Leifer et al., 2001) and it posses many LPS-like activities, such as induction of
LPS-inducible gene expression (Manthey et al., 1992) and activation of NFkB (Perera
et al., 1996). After taxol treatment, a significant inhibition of growth in Tlr4-positive
AtT20 cells similar to the effects of LPS was observed. However, in contrast to LPS,
which did not affect the morphology of mouse AtT20 cells, considerable and dose-
dependent morphological changes were found after taxol treatment. This indicates
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that the mechanism of LPS and taxol is partially different, probably at level of
downstream signalling. Whether Tlr4 is a mediator of effects of taxol also in humans,
is still a matter of debate, since from studies in immune cells of mice it seems that
taxol is not directly interacting with Tlr4 but with MD-2, an adaptor protein of the
active Tlr4 signal complex. In human immune cells, MD-2 is not involved in Tlr4
signal induction. Therefore, in future studies the role of Tlr4 in the mediation of taxol
effects needs to be determined by comparatively stimulating Tlr4-positive and –
negative mouse and human pituitary tumour cell lines with taxol.
In brief, the data shown in the present work extend previous findings on the immune-
endocrine modulatory role of Tlr4 in FS cells of the normal pituitary, and indicate that
Tlr4 might be involved in the pathophysiology and progression of Tlr4-positive
pituitary adenomas through different mechanisms.
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5. SUMMARY
In the present work, the expression and role of Toll-like receptor 4 (Tlr4) in normal
and tumoural epithelial pituitary cells was studied for the first time. Tlr4 is the receptor
for bacterial lipopolysaccharides (LPS) and therefore is involved in mediating the
innate immune response during gram-negative bacteria-induced infection or
inflammation. In addition, Tlr4 may play a role in tumourigenesis, since tumour-
associated components of the extracellular matrix and heat-shock proteins are also
activating ligands of this receptor.
In normal pituitary, Tlr4 is mainly expressed in folliculostellate (FS) cells and plays a
role in immune-endocrine interactions, as previously shown. In the present work,
sporadic expression of Tlr4 was also found in all types of endocrine anterior pituitary
cells. Moreover, a heterogeneous expression of Tlr4 was also found in 26 out of 67
pituitary adenomas studied. In Tlr4-positive adenomas, in most cases a scattered
expression of this receptor in less than 5% of all adenoma cells was observed. The
Tlr4 expression was not linked to a particular adenoma type (hormone-active or –
inactive) or phenotype (micro- or macroadenoma). The tumoural Tlr4 was functional
active, since in IL-6-producing, Tlr4-positive adenomas LPS strongly enhanced the
IL-6 secretion in a dose-dependent manner. The synthetic glucocorticoid
dexamethasone and the p38α MAP kinase inhibitor SB203580 were potent inhibitors
of LPS-induced IL-6 secretion. A heterogeneous Tlr4-expression was also observed
in endocrine epithelial pituitary tumour cell lines some of which were positive
(corticotroph AtT20 cells, inactive human HP75 cells) for Tlr4 whereas no expression
was found in lactosomatotroph GH3 or gonadotroph αT3-1 cells. LPS did not affect
hormone secretion in AtT20 and GH3 cells. In contrast, LPS suppressed growth in
AtT20 cells but had no effect in GH3 cells indicating that LPS can directly inhibit
proliferation of Tlr4-positive cells.
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Taken together, these results suggest that during transient or chronic
infection/inflammation by gram-negative bacteria, LPS may affect tumour growth of
Tlr4-positive pituitary adenomas. Whether LPS inhibits or stimulates pituitary
adenoma development in vivo depends on the co-expression and stimulation of IL-6
(a tumour progression factor for pituitary adenomas) by LPS in Tlr4-positive
adenomas and on the onset and degree of rise of anti-inflammatory-acting
glucocorticoids.
 Not only LPS, but also taxol, a drug used in chemotherapy of cancer and supposed
to act through Tlr4, suppressed growth of AtT20 cells. This indicates that in Tlr4-
positive pituitary adenomas various ligands of Tlr4 such as bacterial or viral
components, pharmacological substances or intratumoral fragments of the
extracellular matrix may affect tumour development. This needs to be clarified in
future studies as well as the question whether in general Tlr4 plays a role in the
tumourigenesis of other types of Tlr4-positive epithelial tumours.
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ZUSAMMENFASSUNG
In der vorliegenden Arbeit wurde erstmals die Expression und Bedeutung des Toll-
like Rezeptors 4 (Tlr4) in normalen und adenomatösen epithelialen
Hypophysenzellen untersucht. Tlr4 ist der Rezeptor für bakterielle
Lipopolysaccharide und ist daher an der Induktion der angeborenen Immunantwort
bei Infektions- oder Entzündungsprozessen beteiligt, die durch gram-negative
Bakterien verursacht werden. Zusätzlich könnte der Tlr4 eine Rolle bei der
Tumorgenese spielen, da Tumor-assoziierte Komponenten der extrazellulären Matrix
oder Heat-Shock Proteine ebenfalls aktivierende Liganden des Tlr4 repräsentieren.
In vorhergehenden Arbeiten wurde gezeigt, dass in der normalen Hypophyse der
Tlr4 vorwiegend in follikulostellaren (FS) Zellen exprimiert wird und für immun-
endokrine Interaktionen von Bedeutung ist. In der vorliegenden Doktorarbeit wurde
eine sporadische Expression des Tlr4 auch in allen endokrinen Vorderlappenzellen
nachgewiesen. Außerdem wurde eine heterogene Expression des Tlr 4 auch in 26
von 67 untersuchten Adenomen gezeigt. In den meisten Fällen wurde in Tlr4-
positiven Adenomen eine verstreute Expression in weniger als 5% aller
Adenomzellen beobachtet. Die Tlr4 Expression korrelierte nicht mit einem speziellen
Adenomtyp (hormonaktiv oder –inaktiv) oder Phänotyp (Mikro- oder Makroadenom).
Der adenomatöse Tlr4 war funktionell aktiv, da LPS in Tlr4-positiven, IL-6-
sezernierenden Adenomen die IL-6 Sekretion dosisabhängig stark stimulierte. Das
synthetische Glukokortikoid Dexamethason und der p38α MAP Kinase Inhibitor SB
203580 waren potente Inhibitoren der LPS-induzierten IL-6 Sekretion. Eine
heterogen Tlr4 Expresion wurde auch in endokrinen Hypophysenzelllinien gefunden,
von denen manche Tlr4-positiv waren (kortikotrope AtT20 und inaktive humane HP75
Zellen), während laktosomatotrope GH3 und gonadotrope αT3-1 Zellen keinen Tlr4
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exprimierten. LPS hatte in AtT20 und GH3 Zellen keinen Einfluß auf die
Hormonsekretion. Im Gegensatz dazu supprimiert LPS das Wachstum von AtT20
Zellen, nicht aber von GH3 Zellen, was darauf hinweist, daß LPS direkt das
Wachstum von Tlr4-positiven Zellen inhibiert.
Zusammengefasst weisen diese Egebnisse darauf hin, daß während transienter oder
chronischer infektiöser bzw. inflammatorischer Prozesse, die durch gram-negative
Bakterien induziert worden sind, LPS da Wachstum von Hypophysentumoren
beeinflussen könnte. Ob LPS in vivo die Hypophysentumor-Entwicklung inhibiert
oder stimuliert, hängt von der Co-Expression und Stimulation von IL-6 (ein
Progressionsfaktor für Hypophysentumoren) durch LPS in Tlr4-positiven Adenomen
ab und vom Einsetzen und dem Ausmaß des Anstiegs von anti-inflammatorisch
wirksamen Glukokortikoiden.
Nicht nur LPS, sondern auch das bei Krebserkrankungen eingesetzte
Chemotherapeutikum Taxol, von dem man annimmt, dass es durch Tlr4 wirksam ist,
inhibierte das Wachstum von AtT20 Zellen. Das läßt vermuten, dass in Tlr4-positiven
Adenomen auch noch weitere Liganden des Tlr4 wie z.B. andere bakterielle oder
virale Bestandteile, Pharmaka oder intratumorale Fragmente der extrazellulären
Matrix die Entwicklung von Hypophysentumoren beeinflussen. Dies muss in
zukünftigen Studien noch geklärt werden, ebenso wie die Frage, ob der Tlr4
allgemein eine Rolle für die Tumorgenese in anderen Tlr4-positiven epithelialen
Tumoren spielt.
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